SCHEMBL1634058

SCHEMBL1634058

COc1cc(OC)c(/C=C/S(=O)(=O)Nc2ccc(OC)c(OC(=O)c3ccc(N)cc3)c2)c(OC)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.43
MAPT P10636 5/20 0.42
ALOX12 P18054 1/20 0.42
KMT2A Q03164 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
PLK1 P53350 4/20 0.41
MET P08581 1/20 0.41
NQO2 P16083 1/20 0.41
FECH P22830 1/20 0.41
CLK3 P49761 1/20 0.41
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HDAC3 O15379 2/20 0.39
HDAC4 P56524 2/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC7 Q8WUI4 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1634098 0.92 PLK1 (0.41) ABCG2MAPTALOX12KMT2ASMN1; SMN2
SCHEMBL1636060 0.90 ALDH1A1 (0.47) ABCG2MAPTALOX12KMT2AMEN1
SCHEMBL1636064 0.90 ALDH1A1 (0.47) ABCG2MAPTALOX12KMT2AMEN1
SCHEMBL1634600 0.87 MAPT (0.46) MAPTKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL1634604 0.87 MAPT (0.46) MAPTKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL1634052 0.86 LMNA (0.43) ABCG2KMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL1634057 0.86 LMNA (0.43) ABCG2KMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL1635791 0.84 NPC1 (0.50) MAPTKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL2212729 0.83 MAPT (0.49) MAPTKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL2213353 0.83 MAPT (0.49) MAPTKMT2ASMN1; SMN2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3138832-A1 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS Temple University - Of The Commonwealth System of Higher Education (US) 2017-03-08 EP claimed
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-03-06 US claimed
EP-3138832-A1 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS Temple University - Of The Commonwealth System of Higher Education (US) 2017-03-08 EP disclosed
US-7932242-B2 Anticancer agents; radiation and chemical resistance TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-04-26 US disclosed
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders PCNA, MKI67, TP53 ABCG2 1761/4885MAPT 2810/4885ALOX12 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.